Lunai Bioworks
LNAI
43 hedge funds and large institutions have $21.5M invested in Lunai Bioworks in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 10 closing their positions.
800% more call options, than puts
Call options by funds: $234K | Put options by funds: $26K
19% more capital invested
Capital invested by funds: $18M → $21.5M (+$3.48M)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
2% less funds holding
Funds holding: 44 → 43 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$1.41M |
| 2 |
Millennium Management
New York
|
+$814K |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$250K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$242K |
| 5 |
Jane Street
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$659K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$572K |
| 3 |
Morgan Stanley
New York
|
-$554K |
| 4 |
D.E. Shaw & Co
New York
|
-$405K |
| 5 |
AGM
Alpine Global Management
New York
|
-$177K |
LNAI Hedge Fund Activity: Q1 2022 in Review
43 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Lunai Bioworks (LNAI) for Q1 2022, worth a combined $21.5M — up 19% from $18M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LNAI and 9 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 14 added.
The largest buyer was Invesco, opening a new position worth an estimated $1.41M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $659K sold.
- 43 institutional investors held Lunai Bioworks (LNAI) as of Q1 2022, down from 44 in Q4 2021.
- Funds reported $21.5M of Lunai Bioworks stock for Q1 2022, up 19% quarter-over-quarter.
- 9 funds opened new Lunai Bioworks positions in Q1 2022 and 10 closed out, a net change of -1 holder.
- The largest Lunai Bioworks buyer in Q1 2022 was Invesco, an estimated $1.41M added.
- The largest Lunai Bioworks seller in Q1 2022 was Renaissance Technologies, an estimated $659K sold.
Based on aggregated 13F filings for Q1 2022.